Australia's 4DMedical secures $100+ M funding to accelerate US expansion

Australia-based 4DMedical, the leader in software-based respiratory imaging technology, has announced $100+ million (AU$150 million) in new institutional placement.

The investment will primarily be leveraged to accelerate US adoption of its class-leading "CT:VQ™" product and significantly boost research and development—bolstering 4D's technology lead in software-based lung imaging.

CT:VQ™ is 4DMedical's FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. 

4DMedical will use the funding to expand US availability of CT:VQ™ and support health systems with implementation at scale, including:

• Commercial expansion across US academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
• Customer success, training, and technical support to help integrate CT:VQ™ into existing clinical workflows and drive consistent utilisation
• Ongoing research and development to expand 4DMedical's technology leadership, product portfolio and capabilities in functional lung imaging
• Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

Following the raise, 4DMedical reported a pro forma cash position exceeding $130+ million (AU$200+ million), which will support the company's US expansion strategy and growing installed base.